Literature DB >> 26780034

The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Angela Ceribelli1,2, Maria De Santis1, Natasa Isailovic1, M Eric Gershwin3, Carlo Selmi4,5.   

Abstract

The pathogenesis of idiopathic inflammatory myositis (IIMs, including polymyositis and dermatomyositis) remains largely enigmatic, despite advances in the study of the role played by innate immunity, adaptive immunity, genetic predisposition, and environmental factors in an orchestrated response. Several factors are involved in the inflammatory state that characterizes the different forms of IIMs which share features and mechanisms but are clearly different with respect to the involved sites and characteristics of the inflammation. Cellular and non-cellular mechanisms of both the immune and non-immune systems have been identified as key regulators of inflammation in polymyositis/dermatomyositis, particularly at different stages of disease, leading to the fibrotic state that characterizes the end stage. Among these, a special role is played by an interferon signature and complement cascade with different mechanisms in polymyositis and dermatomyositis; these differences can be identified also histologically in muscle biopsies. Numerous cellular components of the adaptive and innate immune response are present in the site of tissue inflammation, and the complexity of idiopathic inflammatory myositis is further supported by the involvement of non-immune mechanisms such as hypoxia and autophagy. The aim of this comprehensive review is to describe the major pathogenic mechanisms involved in the onset of idiopathic inflammatory myositis and to report on the major working hypothesis with therapeutic implications.

Entities:  

Keywords:  Cancer; Dermatomyositis; Inflammation; Muscle biopsy; Polymyositis

Mesh:

Year:  2017        PMID: 26780034     DOI: 10.1007/s12016-016-8527-x

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  173 in total

1.  Chronic graft-versus-host disease with skin signs suggestive of dermatomyositis.

Authors:  M J Arin; C Scheid; K Hübel; T Krieg; W Groth; G Haerrmann
Journal:  Clin Exp Dermatol       Date:  2006-01       Impact factor: 3.470

2.  Evidence for a role of type I interferons in the pathogenesis of dermatomyositis.

Authors:  J Wenzel; M Scheler; T Bieber; T Tüting
Journal:  Br J Dermatol       Date:  2005-08       Impact factor: 9.302

3.  Quantification and molecular characterization of regulatory T cells in connective tissue diseases.

Authors:  Leontina Banica; Alina Besliu; Gina Pistol; Crina Stavaru; Ruxandra Ionescu; Ana-Maria Forsea; Cristina Tanaseanu; Sergiu Dumitrache; Dan Otelea; Isabela Tamsulea; Stefanita Tanaseanu; Cristina Chitonu; Simona Paraschiv; Monica Balteanu; Maria Stefanescu; Cristiana Matache
Journal:  Autoimmunity       Date:  2009-01       Impact factor: 2.815

4.  Immune activation at effector and gene expression levels after measles vaccination in healthy individuals: a pilot study.

Authors:  Neelam Dhiman; Inna G Ovsyannikova; Ann L Oberg; Diane E Grill; Robert M Jacobson; Gregory A Poland
Journal:  Hum Immunol       Date:  2006-01-04       Impact factor: 2.850

Review 5.  Immunopathogenesis of juvenile dermatomyositis.

Authors:  Sahil Khanna; Ann M Reed
Journal:  Muscle Nerve       Date:  2010-05       Impact factor: 3.217

6.  Paediatric adverse drug reaction reporting: understanding and future directions.

Authors:  Bruce C Carleton; M Anne Smith; Michaela N Gelin; Susan C Heathcote
Journal:  Can J Clin Pharmacol       Date:  2007-02-12

7.  Genetic polymorphisms of transforming growth factor beta-1 promoter and primary biliary cirrhosis in Japanese patients.

Authors:  Kentaro Kikuchi; Atsushi Tanaka; Masanao Matsushita; Eriko Kitazawa; Naomi Hosoya; Yumi Kawashima; Carlo Selmi; M Eric Gershwin; Hiroshi Miyakawa
Journal:  Ann N Y Acad Sci       Date:  2007-09       Impact factor: 5.691

8.  HLA class II haplotypes differentiate between the adult autoimmune polyglandular syndrome types II and III.

Authors:  B K Flesch; N Matheis; T Alt; C Weinstock; J Bux; G J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

9.  Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity.

Authors:  Pawel Mielnik; Hanna Chwalinska-Sadowska; Ewa Wiesik-Szewczyk; Wlodzimierz Maslinski; Marzena Olesinska
Journal:  Rheumatol Int       Date:  2010-12-04       Impact factor: 2.631

Review 10.  Molecular mimicry and immune-mediated diseases.

Authors:  M B Oldstone
Journal:  FASEB J       Date:  1998-10       Impact factor: 5.191

View more
  17 in total

1.  Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathy.

Authors:  Kevin E McElhanon; Nicholas Young; Jeffrey Hampton; Brian J Paleo; Thomas A Kwiatkowski; Eric X Beck; Ana Capati; Kyle Jablonski; Travis Gurney; Miguel A Lopez Perez; Rohit Aggarwal; Chester V Oddis; Wael N Jarjour; Noah Weisleder
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

Review 2.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

3.  Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.

Authors:  Angela Ceribelli; Natasa Isailovic; Maria De Santis; Elena Generali; Micaela Fredi; Ilaria Cavazzana; Franco Franceschini; Luca Cantarini; Minoru Satoh; Carlo Selmi
Journal:  Clin Rheumatol       Date:  2016-10-20       Impact factor: 2.980

4.  Serum protein biomarkers for juvenile dermatomyositis: a pilot study.

Authors:  Shefa M Tawalbeh; Wilfredo Marin; Gabrielle A Morgan; Utkarsh J Dang; Yetrib Hathout; Lauren M Pachman
Journal:  BMC Rheumatol       Date:  2020-10-01

5.  Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients.

Authors:  Hang Zhou; Yunchao Wang; Kuo Bi; Haiyu Qi; Shuju Song; Mingzhu Zhou; Letian Chen; Guochun Wang; Ting Duan
Journal:  Clin Rheumatol       Date:  2019-01-15       Impact factor: 2.980

Review 6.  Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?

Authors:  Richard D Sontheimer
Journal:  Ann Transl Med       Date:  2018-04

7.  Pervasive inflammatory activation in patients with deficiency in very-long-chain acyl-coA dehydrogenase (VLCADD).

Authors:  Abbe N Vallejo; Henry J Mroczkowski; Joshua J Michel; Michael Woolford; Harry C Blair; Patricia Griffin; Elizabeth McCracken; Stephanie J Mihalik; Miguel Reyes-Mugica; Jerry Vockley
Journal:  Clin Transl Immunology       Date:  2021-06-27

Review 8.  Current Classification and Management of Inflammatory Myopathies.

Authors:  Jens Schmidt
Journal:  J Neuromuscul Dis       Date:  2018

9.  Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis.

Authors:  Tamara Vojinovic; Ilaria Cavazzana; Paolo Ceruti; Micaela Fredi; Denise Modina; Marialma Berlendis; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-03       Impact factor: 8.667

10.  A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children.

Authors:  Feng Jiang; Xiao-Lin Miao; Xiao-Tian Zhang; Feng Yan; Yan Mao; Chu-Yan Wu; Guo-Ping Zhou
Journal:  J Immunol Res       Date:  2021-07-15       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.